Ahmedabad pharma maker of 1,700+ registered generic formulations, exporting to 60+ countries across Africa, Asia and the Americas.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 284 | 346 | 413 | 482 | 573 | 652 | 696 | 738 |
| Borrowings | 5 | 1 | 2 | 2 | 1 | 0 | 0 | 4 |
| Other Liabilities | 58 | 85 | 99 | 83 | 106 | 125 | 139 | 128 |
| Total Liabilities | 367 | 452 | 534 | 587 | 700 | 797 | 855 | 890 |
| AssetsFixed Assets | 91 | 111 | 132 | 151 | 179 | 182 | 185 | 191 |
| CWIP | 0 | 2 | 16 | 7 | 3 | 4 | 3 | 5 |
| Investments | 60 | 81 | 97 | 91 | 139 | 174 | 209 | 209 |
| Other Assets | 216 | 259 | 289 | 339 | 378 | 437 | 458 | 485 |
| Total Assets | 367 | 452 | 534 | 587 | 700 | 797 | 855 | 890 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 51 | 71 | 69 | 76 | 39 | 63 | 93 | 106 |
| Cash from Investing | -22 | -29 | -64 | -78 | -37 | -57 | -79 | -98 |
| Cash from Financing | -30 | -38 | -6 | -3 | -4 | -5 | -6 | 0 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 40 | 65 | 61 | 31 | 26 | 24 | 74 | 82 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (12.9×) and current (14.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 6.3% growth and a 13× exit, ₹615 only delivers your return if you pay ₹328. The price is currently baking in 19% growth.
EPS grows 6.3%/yr for 5 years, then fades to 6% over 2, exits at 13×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 6.3% | 46.66 |
| FY28 | 6.3% | 49.59 |
| FY29 | 6.3% | 52.72 |
| FY30 | 6.3% | 56.04 |
| FY31 | 6.3% | 59.57 |
| FY32 | 6.2% ·fade | 63.23 |
| FY33 | 6.0% ·fade | 67.03 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.